RT - Journal Article T1 - Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside JF - babol-caspjim YR - 2017 JO - babol-caspjim VO - 8 IS - 4 UR - http://caspjim.com/article-1-847-en.html SP - 228 EP - 238 K1 - Cancer K1 - Immunotherapy K1 - Macrophage activating factor K1 - GC-MAF K1 - Vitamin D. AB - Immunotherapy has been used for years in many types of cancer therapy. Recently, cancer immunotherapy has focused on mechanisms which can enhance the development of cell-mediated immunity. Anticancer medications are administered to inhibit immunosuppressive factors such as nagalase enzyme, which is produced by neoplastic cells and destroys macrophage activating factor (Gc-MAF). Anti-neoplastics medications can also enhance immune-cell activity against tumors. Such medications show great potential in cancer immunotherapy using natural human mechanisms against neoplasms. LA eng UL http://caspjim.com/article-1-847-en.html M3 10.22088/cjim.8.4.228 ER -